K. P. Ohman

发表

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

J. Rosenstock, B. Goldstein, D. Anzalone, 2006, Current medical research and opinion.

A comparison of 100 mg atenolol and 100 mg metoprolol once a day at rest and during exercise in hypertensives.

J. Atterhög, B. Karlberg, K. Tolagen, 2009, Acta medica Scandinavica.

Prizidilol, a combined vasodilatory and beta-adrenoceptor blocking drug, in primary hypertension. A long-term efficacy, tolerance and pharmacokinetic study.

B. Karlberg, J. Hed, B. Norlander, 1983, European journal of clinical pharmacology.

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.

B. Fagerberg, S. Tonstad, I. Gause-Nilsson, 2008, Atherosclerosis.

Plasma levels of cyclic GMP and endothelin in postmenopausal women with unstable coronary artery disease.

J. Ahlner, E. Swahn, N. Nielsen, 1999, Scandinavian journal of clinical and laboratory investigation.

Atrial natriuretic factor (ANF 103-126) enhances volume- and pressor-induced heart rate response in the conscious rat.

H. Keiser, E. Marks, K. Ohman, 1990, Acta physiologica Scandinavica.

Labetalol in primary hypertension: a long-term effect and tolerance study

J. Asplund, K. P. Ohman, 1984 .

Circulating plasma prekallikrein and tissue kallikrein in normotensive and hypertensive humans: effects of angiotensin II infusion.

B. Karlberg, K. Ohman, K. P. Ohman, 1998, Clinical and experimental hypertension.

Plasma and tissue kallikrein-kinin systems during acute administration of frusemide in normotensive and hypertensive humans.

B. Karlberg, K. Ohman, K. P. Ohman, 1991, Clinical science.

Circulating kallikreins in normotensive and hypertensive humans: effects of mineralocorticoid administration.

K. P. Ohman, 1997, Blood pressure.